Read this topic

Most dementias give a doctor months or years to think. Creutzfeldt-Jakob disease (CJD, the commonest human prion disease) gives them weeks. A patient who was independently doing the weekly shop can be bed-bound, mute and close to death within six months of the first symptom, and by the time imaging or blood tests would normally be organised at a leisurely pace, the disease has already moved on. That is the entire reason CJD exists as an urgent diagnostic category in psychiatry and neurology: recognising it fast changes what happens next, not just for the patient (early referral to a specialist prion unit, honest palliative planning while the patient can still take part in decisions) but for everyone else who might touch that patient's tissue, since CJD is also an infection-control emergency: contaminated surgical instruments and even corneal or dural grafts have transmitted it between people. Miss the diagnosis and file it away as 'atypical Alzheimer's', and both of those windows close.

Every cell makes a protein called PrP (prion protein) that normally folds into a harmless shape. Folding just means the way a long chain of amino acids (the building blocks of proteins) twists itself into its final three-dimensional shape, the way a strip of paper can be folded into either a flat sheet or a paper aeroplane. In prion disease, some of that protein twists into an abnormal shape instead. The abnormal shape is not just harmless clutter: it acts like a template, physically forcing normal protein molecules that touch it to twist into the same abnormal shape too. Each newly misfolded molecule can then convert its neighbours, and so on, so the damage does not creep in gradually from one broken part; it multiplies, doubling and redoubling, the way one falling domino tips over the next. That is a prion: a protein that behaves, functionally, like an infectious agent, because it is transmissible.

The single fact worth holding onto above all others: CJD moves in weeks to months, not the years-long slow fade of Alzheimer's disease or dementia with Lewy bodies (DLB, a different dementia marked by fluctuating confusion and hallucinations). A patient who has gone from fully independent to needing full care within two or three months should make CJD, not 'unusually aggressive Alzheimer's', the leading diagnosis. A second caveat, easy to forget because CJD is so rare, is that it is a notifiable, transmissible disease: anything that touches high-risk tissue (brain, spinal cord, eye) in a suspected CJD patient, from surgical instruments to donated corneas, has to be tracked and specially decontaminated or destroyed, because ordinary autoclaving does not reliably destroy prions. Treating a rapidly progressive dementia as routine, rather than as a possible biohazard, is the exact mistake this diagnosis exists to prevent.

Compare CJD to Alzheimer's disease, where a sticky protein called amyloid slowly builds up outside brain cells over ten or twenty years before enough damage accumulates to cause symptoms. CJD's misfolded prion protein does not just accumulate, it self-propagates: each abnormal molecule recruits and converts more normal molecules into the same abnormal shape, so the pool of toxic protein grows exponentially rather than by simple addition. Exponential growth is why a process that might take decades if it merely added up instead looks like it is happening within weeks: doubling twelve times turns one abnormal molecule into roughly four thousand, and only a few more doublings takes that into the millions, all within a compressed timeframe once the process starts running. The misfolded protein also resists the brain's normal clean-up machinery, the enzymes that would ordinarily break down and recycle old or damaged proteins, so it piles up inside and around nerve cells faster than it can be cleared. The result, seen under the microscope, is spongiform change: brain tissue riddled with tiny holes, or vacuoles, where nerve cells have died, alongside gliosis (scarring laid down by the brain's support cells) and none of the inflammation you would expect from an ordinary infection. One self-copying misfolded protein, spreading region by region, explains both the speed of the illness and the sponge-like appearance that gives the disease its name.

Three features together point straight at sporadic CJD (the commonest form, roughly 85% of cases, typically striking people in their sixties): a rapidly progressive dementia developing over weeks to months, myoclonus (sudden, brief, shock-like muscle jerks, often set off by a loud noise or being startled), and, as the disease advances, akinetic mutism (the patient is awake but does not move or speak, because the brain circuits needed to initiate action have been overwhelmed). Average survival from first symptom to death is only around six months, strikingly short compared to the many years a typical dementia allows.

Consider a 63-year-old retired electrician brought in because, over the past ten weeks, he has gone from managing his own finances to being unable to dress himself, has started jumping violently at small noises, and increasingly just stares blankly rather than answering questions. His wife also mentions odd jerks of his whole body that look like a sudden hiccup. That combination (a pace measured in weeks, myoclonus, and encroaching mutism) should trigger an urgent CJD work-up rather than a routine dementia referral.

Alzheimer's disease is the most important mimic to exclude, but it progresses over years, not weeks, and myoclonus is a late, uncommon feature rather than an early clue. Dementia with Lewy bodies can also cause fluctuating confusion and, later, some motor slowing, but it unfolds over years, and its hallmark features are vivid visual hallucinations and day-to-day fluctuation rather than myoclonus and a weeks-long collapse. Beyond CJD, other genuinely rapidly progressive dementias are worth knowing: autoimmune encephalitis (the immune system mistakenly attacking brain tissue, sometimes reversible with immune-suppressing treatment), and Hashimoto's encephalopathy (a rare, steroid-responsive brain disturbance linked to thyroid antibodies). Both matter enormously because, unlike CJD, they can potentially be treated, so a rapidly progressive dementia work-up always screens for them before settling on a diagnosis of CJD.

CJD is diagnosed by combining the clinical picture with three real investigations, not by pattern-recognition alone. The EEG (electroencephalogram, a recording of the brain's electrical activity from scalp electrodes) in sporadic CJD classically shows periodic sharp wave complexes: brief, repeating spikes appearing roughly once or twice a second across the whole brain, a pattern distinctive enough to count as supportive diagnostic evidence on its own. CSF (cerebrospinal fluid, sampled by lumbar puncture) is tested for 14-3-3 protein, a marker of rapid neuronal death that is supportive but not specific to CJD, and, increasingly, RT-QuIC (real-time quaking-induced conversion), a newer test that seeds a normal prion protein sample with the patient's CSF and watches whether it starts misfolding, giving much higher specificity than 14-3-3 because it detects the abnormal protein itself rather than a downstream marker of damage. MRI brain, using DWI (diffusion-weighted imaging) and FLAIR sequences, typically shows cortical ribboning (a bright, gyrus-shaped line of signal tracing the folds of the brain's surface) and increased signal in the basal ganglia (the caudate and putamen, deep grey-matter structures involved in movement); variant CJD instead classically shows the pulvinar sign, increased signal in the back part of the thalamus. Together, a compatible clinical course plus any of these three findings (EEG, CSF, or MRI) supports a diagnosis of probable CJD without waiting for the only fully definitive test, which is brain biopsy or post-mortem histology.

Here the honest answer matters more than a comforting one: CJD has no disease-modifying treatment. No drug slows, halts or reverses the underlying prion process, and management is entirely supportive and palliative. That means symptom control (for example, clonazepam or sodium valproate can ease myoclonus, though neither changes the disease course), careful nutrition and skin care as the patient becomes immobile, and early, honest palliative care planning while the patient can still take part in decisions about their own end-of-life wishes, because the decline is so fast that capacity is often lost within weeks of diagnosis. Alongside symptom care, infection-control precautions form a real and separate part of 'management': CJD is a notifiable disease reported to the UK Health Security Agency (UKHSA), whose guidance, aligned with World Health Organization (WHO) infection-control recommendations for prion disease, sets out that any surgical, dental or ophthalmic instruments used on the patient, especially in neurosurgery, need dedicated decontamination protocols or destruction rather than standard sterilisation, because prions resist routine autoclaving. Getting this section right on an exam means resisting the urge to invent a treatment: the correct answer is that management is supportive care plus safety precautions, not a drug.

When a vignette describes a dementia that has progressed from full independence to severe impairment within weeks to a few months, especially alongside myoclonus or a startle-jerk, think CJD before Alzheimer's, and expect the supporting evidence offered to be an EEG showing periodic sharp waves, a CSF RT-QuIC or 14-3-3 result, or an MRI showing cortical ribboning, not a drug treatment option in the answer list, because there isn't one.

CJD is a rapidly fatal dementia, weeks to months rather than years, caused by a self-propagating misfolded prion protein, confirmed by EEG, CSF and MRI findings, and managed with supportive palliative care plus infection-control precautions rather than any disease-modifying drug.